NASDAQ$MBRX
Moleculin Biotech Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the quarter ended September 30, 2021.
Moleculin Biotech reported its financial results for the quarter ended September 30, 2021. The company's research and development expense was $4.1 million. They ended the quarter with $75.2 million of cash and believe that this cash is sufficient to meet its projected operating requirements into 2024.
- Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021
- Preliminary clinical activity for Annamycin seen in interim results from its US Phase 1b/2 clinical trial for the treatment of soft tissue sarcoma (STS) lung metastases
- Received favorable opinion from the MHRA to commence first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19, expected to commence in Q4 2021
- STS lung metastases trial continues to recruit rapidly
Headline financials
Revenue & EPS history
Moleculin · Revenue · Quarterly
$0
Forward guidance
Moleculin anticipates several milestones in the upcoming months, including reporting topline results from ongoing studies and initiating new clinical trials.
Tailwinds
- Report cohort topline results from the ongoing Phase 1/2 study for treatment of AML and report the study's topline results in H2 2021
- Report cohort topline results from the ongoing Phase 1/2 study for treatment of STS lung metastases and report the study's topline results in H2 2021
- Initiate Phase 1/2 study in Europe for the treatment of AML evaluating combination therapy of Annamycin + Ara-C in H2 2021
- Commencement of an investigator-funded, second Phase 1b/2 clinical trial of Annamycin in sarcoma lung metastases in Europe in H1 2022
- Complete Phase 1b portion of ongoing Phase 1b/2 study of Annamycin for the treatment of sarcoma lung metastases in the US in H1 2022
Headwinds
- Filing a US Investigational New Drug application (IND) for the treatment of certain adult cancer(s) with WP1066 and begin to identify an institution to commence an associated investigator-funded Phase 1a/1b study in H2 2021
- Report topline results from Phase 1 physician-sponsored pediatric brain tumor clinical trial in H1 2022
- Facilitate launch of physician-sponsored Phase 2 study of WP1066 for the treatment of pediatric brain tumors including DIPG in H2 2022
- Actively seek collaboration with a strategic partner in the near term for external funding for the continued development of WP1220 in a Phase 2 clinical trial as a topical therapy for CTCL
- Commence Phase 1a study of WP1122 for the treatment of COVID-19 in the UK in H2 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-1.2%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-5.3%
Avg return
30 days after
32%
13 / 41 earnings
Positive
+28.1%
Q4 2019
Best reaction
-20.8%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | +9.8% | — | |
| Q4 2025 | +0.0% | +20.9% | +17.5% | |
| Q3 2025 | -4.4% | -3.5% | -56.1% | |
| Q2 2025 | -4.0% | -11.7% | -46.1% | |
| Q1 2025 | -8.2% | -1.3% | -35.3% | |
| Q4 2024 | -2.8% | -3.7% | -12.8% | |
| Q3 2024 | +3.5% | +6.3% | +3.9% | |
| Q2 2024 | -5.1% | +2.1% | +3.4% | |
| Q1 2024 | +1.9% | +6.7% | -9.2% | |
| Q4 2023 | -20.8% | -16.4% | -29.9% | |
| Q3 2023 | +1.9% | +9.3% | -2.4% | |
| Q2 2023 | -1.3% | -7.5% | -32.7% | |
| Q1 2023 | -14.4% | -21.7% | -23.1% | |
| Q4 2022 | -1.9% | -7.8% | -24.0% | |
| Q3 2022 | +5.1% | +6.1% | +48.6% | |
| Q2 2022 | +9.3% | +3.7% | -12.3% | |
| Q1 2022 | +1.6% | +9.0% | +23.0% | |
| Q4 2021 | -4.4% | -1.7% | +1.1% | |
| Q3 2021 | +0.0% | -6.5% | -5.7% | |
| Q2 2021 | -3.3% | -11.1% | -0.3% | |
| Q1 2021 | -3.8% | -2.1% | -99.7% | |
| Q4 2020 | -1.5% | -6.6% | -11.6% | |
| Q3 2020 | +2.9% | +8.5% | +14.1% | |
| Q2 2020 | -7.4% | -5.6% | -29.0% | |
| Q1 2020 | +0.0% | +0.0% | +11.2% | |
| Q4 2019 | +28.1% | +27.9% | +155.9% | |
| Q3 2019 | +0.9% | -0.9% | -4.7% | |
| Q2 2019 | +6.5% | +10.2% | +13.0% | |
| Q1 2019 | -0.8% | -5.7% | -4.9% | |
| Q4 2018 | +3.8% | -1.5% | -0.8% | |
| Q3 2018 | -3.1% | +6.1% | -3.8% | |
| Q2 2018 | +0.0% | -1.2% | +0.0% | |
| Q1 2018 | -0.6% | -0.6% | +12.1% | |
| Q4 2017 | -3.2% | -1.1% | -0.5% | |
| Q3 2017 | -0.4% | +3.7% | +5.6% | |
| Q2 2017 | -7.7% | -11.8% | -3.7% | |
| Q1 2017 | -4.7% | -4.9% | +0.0% | |
| Q4 2016 | -12.8% | -28.2% | -27.4% | |
| Q3 2016 | -2.4% | +1.7% | -50.5% | |
| Q2 2016 | -1.6% | -6.7% | -1.0% | |
| Q1 2016 | +2.3% | +5.4% | +5.2% | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro